Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Diabetes, Obesity & Metabolism
Emanuel RaschiFabrizio De Ponti

Abstract

Sodium glucose co-transporter-2 inhibitors have attracted the interest of the scientific community following the results from dedicated cardiovascular outcome trials, which demonstrated remarkable reduction in all-cause mortality and other cardiovascular (CV) endpoints with empagliflozin and canagliflozin. These impressive results raised further expectations on real world data from large observational cohort studies. They were designed to address the possible existence of a class effect, and the uncertainty on whether this benefit can be extended from secondary to primary CV prevention of patients with type 2 diabetes. In this review, we collated data from existing observational studies (including the celebrated CVD-REAL cohorts) and critically appraised results and methodological issues with the aim of providing clinical insight, including unsettled aspects, and proposing a research agenda for future investigations.

References

Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Sep 22, 2012·Obstetrics and Gynecology·David A Grimes, Kenneth F Schulz
Jul 6, 2014·PloS One·Georgia SalantiJulian P T Higgins
Dec 17, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Julia C PrenticeSteven D Pizer
Mar 13, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Elisabetta PatornoJohn D Seeger
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jul 9, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jean-Luc Faillie
Nov 9, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Edoardo Mannucci, Matteo Monami
Jan 21, 2017·Journal of the American College of Cardiology·Markus C ElzeStuart J Pocock
Mar 23, 2017·The Journal of Clinical Endocrinology and Metabolism·Konstantinos A ToulisKrishnarajah Nirantharakumar
May 19, 2017·Diabetes, Obesity & Metabolism·Benedetta Maria BonoraGian Paolo Fadini
May 27, 2017·Journal of the American College of Cardiology·Naveed SattarJames L Januzzi
Jun 2, 2017·Diabetes Research and Clinical Practice·Matteo MonamiEdoardo Mannucci
Jun 8, 2017·The New England Journal of Medicine·Michael FralickElisabetta Patorno
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Jul 18, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Amr MakadyUNKNOWN (on behalf of GetReal Work Package 1)
Jul 25, 2017·The Lancet. Diabetes & Endocrinology·Gian Paolo Fadini, Angelo Avogaro
Aug 25, 2017·Clinical Pharmacology and Therapeutics·Jessica M Franklin, Sebastian Schneeweiss
Sep 28, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Auryan SzalatSamuel N Heyman
Oct 2, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Shirley V WangUNKNOWN joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making
Oct 17, 2017·Clinical Pharmacology and Therapeutics·Mehdi NajafzadehSebastian Schneeweiss
Oct 19, 2017·Postgraduate Medicine·Sebastian Filippas-NtekouanMoses S Elisaf
Nov 28, 2017·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·E RaschiE Poluzzi
Nov 28, 2017·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A PerlmanA Szalat
Dec 2, 2017·Diabetes, Obesity & Metabolism·Konstantinos A ToulisKrishnarajah Nirantharakumar

❮ Previous
Next ❯

Citations

Oct 10, 2018·Expert Opinion on Pharmacotherapy·Emanuel RaschiGiulio Marchesini
Mar 29, 2019·Expert Opinion on Pharmacotherapy·Emanuel RaschiFabrizio De Ponti
Sep 2, 2019·Cardiovascular Diabetology·Guntram SchernthanerKārlis Trušinskis
Nov 4, 2020·Expert Opinion on Pharmacotherapy·Emanuel RaschiFabrizio De Ponti
Feb 13, 2021·Cardiovascular Diabetology·Benedetta Maria BonoraGian Paolo Fadini
Feb 25, 2020·Internal Medicine Journal·Amy L HardingJohn M Wentworth
Apr 22, 2021·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Lianglan ShenYan Shen

❮ Previous
Next ❯

Methods Mentioned

BETA
amputations
amputation

Software Mentioned

OBSERVE
CANVAS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

© 2022 Meta ULC. All rights reserved